Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2020

View Archived Issues

New mouse model of MS reveals that oligodendroglia-specific connexin 47 regulates neuroinflammation

Matinas BioPharma initiates ENHANCE-IT study of MAT-9001

BioCryst initiates proof-of-concept trial of BCX-9930 in PNH

BITRAP demonstrates promising efficacy in preclinical models of rheumatoid arthritis

Servier publishes phase II data from RESTORE BRAIN study of S-44819

Phase I data for enzalutamide plus capivasertib in mCRPC

Enanta Pharmaceuticals patents MAP3K5 inhibitors

BenevolentAI Bio divulges new NTRK1 inhibitors

Blocking trash trashes MSI-hi tumors

Adlai Nortye describes hSTING receptor agonists

Il-Yang Pharmaceutical presents new antivirals

JAGUAHR Therapeutics patents new AhR antagonists

Indian approval of saroglitazar for noncirrhotic NASH

New gene fusion EWSR1-PATZ1 found in renal cell carcinoma

NCS-01 begins phase I/II study in patients with acute ischemic stroke

Enrollment open in phase I study of FT-596 for relapsed/refractory B-cell lymphoma or CLL

Gene therapy converts astrocytes into GABAergic neurons, alleviating motor deficits in HD models

Endocytosis inhibitor improves anticancer MAb efficacy

Gene rearrangements involving HMGA1/2 found in spindle cell/pleomorphic lipomas

Third cohort underway in phase I trial of Actimab-A plus CLAG-M for relapsed/refractory AML

Arcturus partners with Duke-NUS on COVID-19 vaccine development

Camrelizumab approved in China for advanced hepatocellular carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...